Toshiba America Medical Systems

Nov 8, 2005

2005 11 08 15 36 23 706

Toshiba of Tustin, CA, will give RSNA attendees a look at Xario and Famio, two new ultrasound systems the company introduced in 2005. Both units have received FDA clearance.

Xario features 4D imaging, Toshiba's ApliPure spatial and frequency compound imaging, advanced dynamic flow, pulse-subtraction harmonics, multiplanar volume rendering, and Fast Fusion 3D. The system is positioned a step below Toshiba's high-end Aplio ultrasound system, with an average price between $90,000 and $140,000, depending on configuration.

Xario is intended to serve the general, breast, and vascular imaging segments, as well as ob/gyn, intraoperative, cardiology, renal, and interventional radiology applications.

Toshiba is positioning Famio, a grayscale ultrasound system, at the economy end of its product line. Famio offers a 14-inch noninterlaced monitor, two transducer ports, tissue harmonic imaging, and a high-frame-rate function.

Toshiba sees Famio as suitable for general, breast, and small parts imaging, along with ob/gyn and urology. It has a target price of $18,000 to $22,000, depending on configuration.

By Wayne Forrest
AuntMinnie.com contributing writer
November 9, 2005

Copyright © 2005 AuntMinnie.com

(A) SHAP summary plot shows the global contributions of variables to the model predictions. (B-E) Local explanation of the model for a single instance of ovarian endometrioid carcinoma: SHAP waterfall plot (B), ultrasound grayscale image (C), ultrasound color Doppler image (D), and 10×10 histopathological image (E). Images are available for republishing under a Creative Commons license (CC BY-NC-ND 4.0).

Deep-learning radiomics model aids in ovarian cancer diagnosis

March 5, 2025

2025 03 04 Radiology Hrus Mrn Neuropathy Thumbnail

MRI, ultrasound have tradeoffs in diagnosing neuropathies

March 4, 2025

ECR: CEUS adds value to spleen trauma management

February 28, 2025

Ultrasound Diagnostic Control Panel 400

Ultrasound falls short for detecting endometrial cancer in Black women

February 21, 2025

Deep-learning radiomics model aids in ovarian cancer diagnosis

By Amerigo Allegretto

An ensemble model combining clinical variables, O-RADS, and deep learning radiomics can diagnose ovarian tumors.

March 5, 2025

(A) SHAP summary plot shows the global contributions of variables to the model predictions. (B-E) Local explanation of the model for a single instance of ovarian endometrioid carcinoma: SHAP waterfall plot (B), ultrasound grayscale image (C), ultrasound color Doppler image (D), and 10×10 histopathological image (E). Images are available for republishing under a Creative Commons license (CC BY-NC-ND 4.0).

MRI, ultrasound have tradeoffs in diagnosing neuropathies

By Amerigo Allegretto

MRI and ultrasound have tradeoffs in diagnosing peripheral neuropathies of the upper extremity.

March 4, 2025

2025 03 04 Radiology Hrus Mrn Neuropathy Thumbnail

ECR: CEUS adds value to spleen trauma management

By Amerigo Allegretto

CEUS could be a suitable alternative to CT for early detection of complications in splenic trauma that’s nonoperatively managed.

February 28, 2025

Ultrasound falls short for detecting endometrial cancer in Black women

By Amerigo Allegretto

Ultrasound-based strategies fall short of biopsy for detecting endometrial cancer in non-Hispanic Black women.

February 21, 2025

Ultrasound Diagnostic Control Panel 400

LUS reliable for care strategies in infants with RDS

By Amerigo Allegretto

Lung ultrasound (LUS) scoring is reliable for determining whether preterm newborns need surfactant for suspected respiratory distress syndrome (RDS).

February 20, 2025

1Each lung has been split into three parts. Each area has been given a score between 0 and 3. Score values are shown in Ultrasonograms to match 4 different patterns. During a longitudinal scan with a high-resolution linear probe, pictures of patterns were taken. The scores are as follows: 0 means A pattern, 1 means B pattern, 2 means severe B pattern, and 3 means extended consolidation. Images available for publishing under a creative commons license, CC BY-NC-ND 4.0.

Lung biomarkers inform patient selection for EBUS-TBNA

By Amerigo Allegretto

Lung imaging biomarkers can inform patient selection for endobronchial ultrasound-guided transbronchial needle aspiration (EBUS-TBNA).

February 19, 2025

2025 02 19 Ajr Lung Images Thumbnail

Ultrasound rules out N2 disease in PET-negative lung cancer patients

By Amerigo Allegretto

Combined endobronchial ultrasound and endoscopic ultrasound is a reliable tool for ruling out N2 disease in PET-negative lung cancer patients.

February 12, 2025

Cryoablation leads to low breast cancer recurrence rates

By Amerigo Allegretto

Ultrasound-guided cryoablation can be considered for breast cancer patients who are poor surgical candidates or who refuse surgery.

February 7, 2025

Ultrasound, histopathological diagnoses assess benign breast lesions

By Amerigo Allegretto

Sonographic imaging descriptors and histopathological diagnoses are needed for more accurate assessment of benign breast lesions.

February 3, 2025

Ultrasound Breast 400

AI assistance improves CHD detection on prenatal ultrasound

By Amerigo Allegretto

AI boosts detection of major congenital heart defects (CHDs) on prenatal ultrasound, suggest findings presented at the Annual Pregnancy Meeting of the SMFM.

January 31, 2025

Smfm Ultrasound Ai Fetal Thumbnail

LI-RADS ultrasound surveillance version 2024 improves HCC detection

By Amerigo Allegretto

The 2024 version of the LI-RADS Ultrasound Surveillance system improves detection of hepatocellular carcinoma (HCC) over earlier iterations.

January 22, 2025

(A,B) Images from an initial ultrasound examination showed no identifiable lesions and received a consensus ultrasound category of US-1. Nearly the entire liver is visualized, with minimal shadowing (“s”, A and B), and the examination received consensus result of VIS-A. The AFP level was 7.1 ng/mL on assessment six months before the ultrasound, 9.1 ng/mL on assessment three months before examination, and 14.2 ng/mL on assessment on exam day. The AFP result was thus assessed as positive based on a progressive increase on two consecutive tests. The atient was considered to have negative surveillance result according to LI-RADS Ultrasound Surveillance v2017, but positive surveillance result according to LI-RADS Ultrasound Surveillance v2024. (C-D) Axial arterial-phase (C) and portal-venous phase (D) T1-weighted images from subsequent gadoxetic acid-enhanced MRI show a 2-cm arterial-phase hyperenhancing observation (arrow, C) with portal-venous washout (arrow, D) in segment 7. This observation was classified on MRI as LR-5, thus meeting the present study’s reference standard for diagnosis of HCC. The mass is located in the periphery of the liver, an anatomic area where ultrasound visualization can be challenging due to shadowing.

CEUS resolves indeterminate CT, MRI liver observations

By Amerigo Allegretto

Contrast-enhanced ultrasound (CEUS) can resolve some high-risk indeterminate liver observations initially seen on CT or MRI.

January 21, 2025

Images depict a 49-year-old female participant with cryptogenic cirrhosis who presented with a 3.2-cm liver lesion. This biopsy-confirmed hepatocellular carcinoma (HCC) with an initial categorization of Liver Imaging Reporting and Data System (LI-RADS) category LR-4 (probably HCC) at CT was upgraded to LR-5 (definitely HCC) at contrast-enhanced ultrasound (CEUS). (A) Precontrast CT images in the liver show vague hypoattenuation in the medial left hepatic lobe (arrows). (B) Arterial phase images demonstrate no definite arterial phase hyperenhancement (arrows). (C) Washout and an enhancing capsule (arrows) on a late-phase image resulted in an LR-4 categorization. (D) B-mode ultrasound shows a round hypoechoic nodule (arrows). (E) An early-phase CEUS image shows clear arterial-phase hyperenhancement (arrows); (F) No washout at one minute (arrows), and (G) late, mild washout at four minutes (arrows) resulted in a CEUS LR-5 categorization.

Page 1 of 514